Structure Therapeutics Financial Results and Recent Highlights

 Structure Therapeutics (NASDAQ: GPCR) announced completion of enrollment for its aleniglipron obesity treatment studies ACCESS and ACCESS II, with topline data expected by year-end 2025. The studies, involving over 300 patients, will evaluate doses up to 240mg with optimized titration regiments.

The company reported strong financials with $883.5 million in cash and investments, expected to fund operations through 2027. R&D expenses increased to $108.8 million for 2024, up from $70.1 million in 2023. Net loss for 2024 was $122.5 million.

Structure Therapeutics is advancing its oral small molecule obesity portfolio, including ACCG-2671, an oral amylin receptor agonist expected to begin Phase 1 trials by year-end 2025. The company also maintains pipeline programs targeting GIPR, GCGR, and APJR for obesity treatment.

Structure Therapeutics' Q4 and full-year 2024 results reveal a company strategically positioned in the highly competitive obesity therapeutics market with two key differentiators: oral administration and a multi-modal approach targeting various metabolic pathways.

The completion of enrollment in both ACCESS studies for aleniglipron represents a significant operational achievement, particularly as the company describes it as the "second most advanced oral GLP-1 small molecule" in development. This positions Structure behind Pfizer's danuglipron but potentially ahead of other oral GLP-1 competitors. The anticipated 36-week data by year-end 2025 will be critical, as this duration approaches the timeframe needed to demonstrate meaningful efficacy and safety for obesity therapeutics, though full approval would typically require longer studies.

Financially, the $883.5 million cash position provides substantial runway through 2027 for current operations and preparing aleniglipron for Phase 3, but notably excludes funding for the actual Phase 3 program itself. This is significant as obesity drug registrational trials typically cost $200-300 million at minimum, suggesting a likely capital raise before Phase 3 initiation despite the current strong balance sheet.

The 67.5% year-over-year increase in R&D spending to $108.8 million reflects appropriate investment in pipeline advancement, while the 51% increase in G&A expenses to $49.4 million aligns with infrastructure building for a clinical-stage company preparing for late-stage development.

https://www.stocktitan.net/news/GPCR/structure-therapeutics-reports-fourth-quarter-and-full-year-2024-sez5oahxbmyg.html